Ischemic brain injury: New insights on the protective role of melatonin

Free Radical Biology and Medicine

Volumn 104, Issue , 2017, Pages 32-53

  Ramos, Eva ^a   Patiño, Paloma ^b   Reiter, Russel J ^c   Gil Martín, Emilio ^d   Marco Contelles, José ^e   Parada, Esther ^f,g   los Rios, Cristobal de ^f,g   Romero, Alejandro ^a   Egea, Javier ^f,g  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c University of Texas Health Science Center   (United States)

^d UNIVERSITY OF VIGO   (Spain)

^e INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Brain ischemia; Free radicals; Melatonin; Neuroprotection

Indexed keywords

CALCIUM; ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SILENT INFORMATION REGULATOR 1; SILENT INFORMATION REGULATOR PROTEIN; UNCLASSIFIED DRUG; ANTIOXIDANT; NEUROPROTECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; CELL PROLIFERATION; DRUG SAFETY; EXCITOTOXICITY; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEWBORN DISEASE; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; CEREBROVASCULAR ACCIDENT; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIOXIDANTS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CALCIUM; HUMANS; MELATONIN; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; STROKE; SYNAPTIC TRANSMISSION;

EID: 85008936669     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.01.005     Document Type: Review

References (336)

1. [1] Flynn, R.W., MacWalter, R.S., Doney, A.S., The cost of cerebral ischaemia. Neuropharmacology 55 (2008), 250–256.
2. [2] Mathers, C.D., Boerma, T., Ma Fat, D., Global and regional causes of death. Br. Med Bull. 92 (2009), 7–32.
3. [3] Ito, H., Kanno, I., Ibaraki, M., Hatazawa, J., Miura, S., Changes in human cerebral blood flow and cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. J. Cereb. Blood Flow Metab. 23 (2003), 665–670.
4. [4] Hossmann, K.A., Viability thresholds and the penumbra of focal ischemia. Ann. Neurol. 36 (1994), 557–565.
5. [5] Choi, D.W., Ischemia-induced neuronal apoptosis. Curr. Opin. Neurobiol. 6 (1996), 667–672.
6. [6] Lee, J.M., Zipfel, G.J., Choi, D.W., The changing landscape of ischaemic brain injury mechanisms. (A7-14) Nature, 399, 1999 (A7-14).
7. [7] Tissue plasminogen activator for acute ischemic stroke, The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med 333 (1995), 1581–1587.
8. [8] Zivin, J.A., Fisher, M., DeGirolami, U., Hemenway, C.C., Stashak, J.A., Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230 (1985), 1289–1292.
9. [9] O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H., Howells, D.W., 1,026 experimental treatments in acute stroke. Ann. Neurol. 59 (2006), 467–477.
10. [10] Lo, E.H., Moskowitz, M.A., Jacobs, T.P., Exciting, radical, suicidal: how brain cells die after stroke. Stroke 36 (2005), 189–192.
11. [11] Paschen, W., Role of calcium in neuronal cell injury: which subcellular compartment is involved?. Brain Res. Bull. 53 (2000), 409–413.
12. [12] Chan, P.H., Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21 (2001), 2–14.
13. [13] Niizuma, K., Yoshioka, H., Chen, H., Kim, G.S., Jung, J.E., Katsu, M., Okami, N., Chan, P.H., Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys. Acta 1802 (2010), 92–99.
14. [14] Iadecola, C., Alexander, M., Cerebral ischemia and inflammation. Curr. Opin. Neurol. 14 (2001), 89–94.
15. [15] Rothman, S.M., Olney, J.W., Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19 (1986), 105–111.
16. [16] Arundine, M., Tymianski, M., Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34 (2003), 325–337.
17. [17] Sattler, R., Charlton, M.P., Hafner, M., Tymianski, M., Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J. Neurochem. 71 (1998), 2349–2364.
18. [18] Siesjo, B.K., Cell damage in the brain: a speculative synthesis. J. Cereb. Blood Flow. Metab. 1 (1981), 155–185.
19. [19] Abe, K., Aoki, M., Kawagoe, J., Yoshida, T., Hattori, A., Kogure, K., Itoyama, Y., Ischemic delayed neuronal death. A mitochondrial hypothesis. Stroke 26 (1995), 1478–1489.
20. [20] Singh, M.H., Brooke, S.M., Zemlyak, I., Sapolsky, R.M., Evidence for caspase effects on release of cytochrome c and AIF in a model of ischemia in cortical neurons. Neurosci. Lett. 469 (2010), 179–183.
21. [21] Kirkland, R.A., Franklin, J.L., Evidence for redox regulation of cytochrome C release during programmed neuronal death: antioxidant effects of protein synthesis and caspase inhibition. J. Neurosci. 21 (2001), 1949–1963.
22. [22] Lemasters, J.J., Nieminen, A.L., Qian, T., Trost, L.C., Herman, B., The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury. Mol. Cell Biochem. 174 (1997), 159–165.
23. [23] Giorgio, V., von Stockum, S., Antoniel, M., Fabbro, A., Fogolari, F., Forte, M., Glick, G.D., Petronilli, V., Zoratti, M., Szabo, I., Lippe, G., Bernardi, P., Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc. Natl. Acad. Sci. USA 110 (2013), 5887–5892.
24. [24] Abeti, R., Abramov, A.Y., Mitochondrial Ca(2+) in neurodegenerative disorders. Pharm. Res. 99 (2015), 377–381.
25. [25] Moskowitz, M.A., Lo, E.H., Iadecola, C., The science of stroke: mechanisms in search of treatments. Neuron 67 (2010), 181–198.
26. [26] Chouchani, E.T., Pell, V.R., Gaude, E., Aksentijevic, D., Sundier, S.Y., Robb, E.L., Logan, A., Nadtochiy, S.M., Ord, E.N., Smith, A.C., Eyassu, F., Shirley, R., Hu, C.H., Dare, A.J., James, A.M., Rogatti, S., Hartley, R.C., Eaton, S., Costa, A.S., Brookes, P.S., Davidson, S.M., Duchen, M.R., Saeb-Parsy, K., Shattock, M.J., Robinson, A.J., Work, L.M., Frezza, C., Krieg, T., Murphy, M.P., Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515 (2014), 431–435.
27. [27] Fukuyama, N., Takizawa, S., Ishida, H., Hoshiai, K., Shinohara, Y., Nakazawa, H., Peroxynitrite formation in focal cerebral ischemia-reperfusion in rats occurs predominantly in the peri-infarct region. J. Cereb. Blood Flow Metab. 18 (1998), 123–129.
28. [28] Pacher, P., Beckman, J.S., Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87 (2007), 315–424.
29. [29] Forstermann, U., Boissel, J.P., Kleinert, H., Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12 (1998), 773–790.
30. [30] Moncada, S., Palmer, R.M., Higgs, E.A., Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem. Pharmcol. 38 (1989), 1709–1715.
31. [31] Beckman, J.S., Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9 (1996), 836–844.
32. [32] Dziedzic, T., Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev. Neurother. 15 (2015), 523–531.
33. [33] Chen, G.Y., Nunez, G., Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10 (2010), 826–837.
34. [34] Gelderblom, M., Leypoldt, F., Steinbach, K., Behrens, D., Choe, C.U., Siler, D.A., Arumugam, T.V., Orthey, E., Gerloff, C., Tolosa, E., Magnus, T., Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40 (2009), 1849–1857.
35. [35] Kolaczkowska, E., Kubes, P., Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13 (2013), 159–175.
36. [36] Pocock, J.M., Kettenmann, H., Neurotransmitter receptors on microglia. Trends Neurosci. 30 (2007), 527–535.
37. [37] Hardeland, R., Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 35 (2009), 183–192.
38. [38] Vriend, J., Reiter, R.J., Melatonin feedback on clock genes: a theory involving the proteasome. J. Pineal Res. 58 (2015), 1–11.
39. [39] Menendez-Pelaez, A., Reiter, R.J., Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J. Pineal Res. 15 (1993), 59–69.
40. [40] Venegas, C., Garcia, J.A., Escames, G., Ortiz, F., Lopez, A., Doerrier, C., Garcia-Corzo, L., Lopez, L.C., Reiter, R.J., Acuna-Castroviejo, D., Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res. 52 (2012), 217–227.
41. [41] Acuna-Castroviejo, D., Escames, G., Venegas, C., Diaz-Casado, M.E., Lima-Cabello, E., Lopez, L.C., Rosales-Corral, S., Tan, D.X., Reiter, R.J., Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol. Life Sci. 71 (2014), 2997–3025.
42. [42] Reiter, R.J., Richardson, B.A., Johnson, L.Y., Ferguson, B.N., Dinh, D.T., Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science 210 (1980), 1372–1373.
43. [43] Reiter, R.J., Craft, C.M., Johnson, J.E., Jr, King, T.S., Richardson, B.A., Vaughan, G.M., Vaughan, M.K., Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 109 (1981), 1295–1297.
44. [44] Fiorina, P., Lattuada, G., Ponari, O., Silvestrini, C., DallAglio, P., Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet 347 (1996), 692–693.
45. [45] Ritzenthaler, T., Nighoghossian, N., Berthiller, J., Schott, A.M., Cho, T.H., Derex, L., Brun, J., Trouillas, P., Claustrat, B., Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke. J. Pineal Res. 46 (2009), 349–352.
46. [46] Reiter, R.J., Tan, D.X., Kim, S.J., Cruz, M.H., Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct. Funct. 219 (2014), 1873–1887.
47. [47] Uduma, F.U., Fokam, P., Okere, P.C.N., Motah, M., Incidence of physiological pineal gland and choroid plexus calcifications in cranio-cerebral computed tomograms in Douala, Cameroon. Glob. J. Med. Res. 11 (2011), 5–11.
48. [48] Makomela, N.M., [Elements of system semiotics of the brain and head with cranial vessels of patients with stroke and with risk of stroke development]. Lik. Sprav., 2007, 47–50.
49. [49] Kitkhuandee, A., Sawanyawisuth, K., Johns, J., Kanpittaya, J., Tuntapakul, S., Johns, N.P., Pineal calcification is a novel risk factor for symptomatic intracerebral hemorrhage. Clin. Neurol. Neurosurg. 121 (2014), 51–54.
50. [50] Kitkhuandee, A., Sawanyawisuth, K., Johns, N.P., Kanpittaya, J., Johns, J., Pineal calcification is associated with symptomatic cerebral infarction. J. Stroke Cerebrovasc. Dis. 23 (2014), 249–253.
51. [51] Kondziolka, D., Wechsler, L., Goldstein, S., Meltzer, C., Thulborn, K.R., Gebel, J., Jannetta, P., DeCesare, S., Elder, E.M., McGrogan, M., Reitman, M.A., Bynum, L., Transplantation of cultured human neuronal cells for patients with stroke. Neurology 55 (2000), 565–569.
52. [52] Borlongan, C.V., Sumaya, I., Moss, D., Kumazaki, M., Sakurai, T., Hida, H., Nishino, H., Melatonin-secreting pineal gland: a novel tissue source for neural transplantation therapy in stroke. Cell Transpl. 12 (2003), 225–234.
53. [53] Kilic, E., Ozdemir, Y.G., Bolay, H., Kelestimur, H., Dalkara, T., Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J. Cereb. Blood Flow. Metab. 19 (1999), 511–516.
54. [54] Manev, H., Uz, T., Kharlamov, A., Joo, J.Y., Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. 10 (1996), 1546–1551.
55. [55] Joo, J.Y., Uz, T., Manev, H., Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Restor. Neurol. Neurosci. 13 (1998), 185–191.
56. [56] De Butte, M., Fortin, T., Pappas, B.A., Pinealectomy: behavioral and neuropathological consequences in a chronic cerebral hypoperfusion model. Neurobiol. Aging 23 (2002), 309–317.
57. [57] Kilic, E., Kilic, U., Reiter, R.J., Bassetti, C.L., Hermann, D.M., Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt. J. Pineal Res. 39 (2005), 151–155.
58. [58] Kilic, U., Yilmaz, B., Reiter, R.J., Yuksel, A., Kilic, E., Effects of memantine and melatonin on signal transduction pathways vascular leakage and brain injury after focal cerebral ischemia in mice. Neuroscience 237 (2013), 268–276.
59. [59] Wang, X., Figueroa, B.E., Stavrovskaya, I.G., Zhang, Y., Sirianni, A.C., Zhu, S., Day, A.L., Kristal, B.S., Friedlander, R.M., Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke 40 (2009), 1877–1885.
60. [60] Roseboom, P.H., Namboodiri, M.A., Zimonjic, D.B., Popescu, N.C., Rodriguez, I.R., Gastel, J.A., Klein, D.C., Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol. Brain Res. 63 (1998), 189–197.
61. [61] Kasahara, T., Abe, K., Mekada, K., Yoshiki, A., Kato, T., Genetic variation of melatonin productivity in laboratory mice under domestication. Proc. Natl. Acad. Sci. USA 107 (2010), 6412–6417.
62. [62] Waller, K.L., Mortensen, E.L., Avlund, K., Fagerlund, B., Lauritzen, M., Gammeltoft, S., Jennum, P., Melatonin and cortisol profiles in late midlife and their association with age-related changes in cognition. Nat. Sci. Sleep. 8 (2016), 47–53.
63. [63] Mishima, K., Tozawa, T., Satoh, K., Matsumoto, Y., Hishikawa, Y., Okawa, M., Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psychiatry 45 (1999), 417–421.
64. [64] Acuna Castroviejo, D., Lopez, L.C., Escames, G., Lopez, A., Garcia, J.A., Reiter, R.J., Melatonin-mitochondria interplay in health and disease. Curr. Top. Med. Chem. 11 (2011), 221–240.
65. [65] Sanderson, T.H., Reynolds, C.A., Kumar, R., Przyklenk, K., Huttemann, M., Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol. Neurobiol. 47 (2013), 9–23.
66. [66] Lipton, P., Ischemic cell death in brain neurons. Physiol. Rev. 79 (1999), 1431–1568.
67. [67] Agardh, C.D., Zhang, H., Smith, M.L., Siesjo, B.K., Free radical production and ischemic brain damage: influence of postischemic oxygen tension. Int J. Dev. Neurosci. 9 (1991), 127–138.
68. [68] Flamm, E.S., Demopoulos, H.B., Seligman, M.L., Poser, R.G., Ransohoff, J., Free radicals in cerebral ischemia. Stroke 9 (1978), 445–447.
69. [69] Reiter, R.J., Paredes, S.D., Manchester, L.C., Tan, D.X., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem Mol. Biol. 44 (2009), 175–200.
70. [70] Manchester, L.C., Coto-Montes, A., Boga, J.A., Andersen, L.P., Zhou, Z., Galano, A., Vriend, J., Tan, D.X., Reiter, R.J., Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J. Pineal Res. 59 (2015), 403–419.
71. [71] Barlow-Walden, L.R., Reiter, R.J., Abe, M., Pablos, M., Menendez-Pelaez, A., Chen, L.D., Poeggeler, B., Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 26 (1995), 497–502.
72. [72] Rodriguez, C., Mayo, J.C., Sainz, R.M., Antolin, I., Herrera, F., Martin, V., Reiter, R.J., Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36 (2004), 1–9.
73. [73] Pablos, M.I., Reiter, R.J., Ortiz, G.G., Guerrero, J.M., Agapito, M.T., Chuang, J.I., Sewerynek, E., Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem. Int. 32 (1998), 69–75.
74. [74] Saito, A., Maier, C.M., Narasimhan, P., Nishi, T., Song, Y.S., Yu, F., Liu, J., Lee, Y.S., Nito, C., Kamada, H., Dodd, R.L., Hsieh, L.B., Hassid, B., Kim, E.E., Gonzalez, M., Chan, P.H., Oxidative stress and neuronal death/survival signaling in cerebral ischemia. Mol. Neurobiol. 31 (2005), 105–116.
75. [75] Li, X.J., Zhang, L.M., Gu, J., Zhang, A.Z., Sun, F.Y., Melatonin decreases production of hydroxyl radical during cerebral ischemia-reperfusion. Zhongguo Yao Li Xue Bao 18 (1997), 394–396.
76. [76] Chen, T.Y., Lee, M.Y., Chen, H.Y., Kuo, Y.L., Lin, S.C., Wu, T.S., Lee, E.J., Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J. Pineal Res. 40 (2006), 242–250.
77. [77] Bolanos, J.P., Almeida, A., Roles of nitric oxide in brain hypoxia-ischemia. Biochim. Biophys. Acta 1411 (1999), 415–436.
78. [78] Li, H., Wang, Y., Feng, D., Liu, Y., Xu, M., Gao, A., Tian, F., Zhang, L., Cui, Y., Wang, Z., Chen, G., Alterations in the time course of expression of the Nox family in the brain in a rat experimental cerebral ischemia and reperfusion model: effects of melatonin. J. Pineal Res. 57 (2014), 110–119.
79. [79] Luque Contreras, D., Vargas Robles, H., Romo, E., Rios, A., Escalante, B., The role of nitric oxide in the post-ischemic revascularization process. Pharmacol. Ther. 112 (2006), 553–563.
80. [80] Liu, H., Li, J., Zhao, F., Wang, H., Qu, Y., Mu, D., Nitric oxide synthase in hypoxic or ischemic brain injury. Rev. Neurosci. 26 (2015), 105–117.
81. [81] Guerrero, J.M., Reiter, R.J., Ortiz, G.G., Pablos, M.I., Sewerynek, E., Chuang, J.I., Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J. Pineal Res. 23 (1997), 24–31.
82. [82] Pei, Z., Fung, P.C., Cheung, R.T., Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J. Pineal Res. 34 (2003), 110–118.
83. [83] Pei, Z., Pang, S.F., Cheung, R.T., Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 34 (2003), 770–775.
84. [84] Koh, P.O., Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J. Vet. Med. Sci. 70 (2008), 747–750.
85. [85] Han, F., Chen, Y.X., Lu, Y.M., Huang, J.Y., Zhang, G.S., Tao, R.R., Ji, Y.L., Liao, M.H., Fukunaga, K., Qin, Z.H., Regulation of the ischemia-induced autophagy-lysosome processes by nitrosative stress in endothelial cells. J. Pineal Res. 51 (2011), 124–135.
86. [86] Sinha, K., Degaonkar, M.N., Jagannathan, N.R., Gupta, Y.K., Effect of melatonin on ischemia reperfusion injury induced by middle cerebral artery occlusion in rats. Eur. J. Pharm. 428 (2001), 185–192.
87. [87] Ozacmak, V.H., Barut, F., Ozacmak, H.S., Melatonin provides neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats. J. Pineal Res. 47 (2009), 156–163.
88. [88] Wakatsuki, A., Okatani, Y., Izumiya, C., Ikenoue, N., Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J. Pineal Res. 26 (1999), 147–152.
89. [89] Cuzzocrea, S., Costantino, G., Gitto, E., Mazzon, E., Fulia, F., Serraino, I., Cordaro, S., Barberi, I., De Sarro, A., Caputi, A.P., Protective effects of melatonin in ischemic brain injury. J. Pineal Res. 29 (2000), 217–227.
90. [90] Wakatsuki, A., Okatani, Y., Shinohara, K., Ikenoue, N., Fukaya, T., Melatonin protects against ischemia/reperfusion-induced oxidative damage to mitochondria in fetal rat brain. J. Pineal Res. 31 (2001), 167–172.
91. [91] Tan, D.X., Manchester, L.C., Hardeland, R., Lopez-Burillo, S., Mayo, J.C., Sainz, R.M., Reiter, R.J., Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res. 34 (2003), 75–78.
92. [92] Reiter, R.J., Tan, D.X., Galano, A., Melatonin: exceeding expectations. Physiol. (Bethesda) 29 (2014), 325–333.
93. [93] Reiter, R.J., Tan, D.X., Fuentes-Broto, L., Melatonin: a multitasking molecule. Prog. Brain Res. 181 (2010), 127–151.
94. [94] Szczepanik, M., Melatonin and its influence on immune system. J. Physiol. Pharmcol. 58:Suppl 6 (2007), 115–124.
95. [95] Carrillo-Vico, A., Reiter, R.J., Lardone, P.J., Herrera, J.L., Fernandez-Montesinos, R., Guerrero, J.M., Pozo, D., The modulatory role of melatonin on immune responsiveness. Curr. Opin. Invest. Drugs 7 (2006), 423–431.
96. [96] Zhao, L., An, R., Yang, Y., Yang, X., Liu, H., Yue, L., Li, X., Lin, Y., Reiter, R.J., Qu, Y., Melatonin alleviates brain injury in mice subjected to cecal ligation and puncture via attenuating inflammation, apoptosis, and oxidative stress: the role of SIRT1 signaling. J. Pineal Res. 59 (2015), 230–239.
97. [97] Soybir, G., Topuzlu, C., Odabas, O., Dolay, K., Bilir, A., Koksoy, F., The effects of melatonin on angiogenesis and wound healing. Surg. Today 33 (2003), 896–901.
98. [98] Reiter, R.J., Tan, D.X., Manchester, L.C., Pilar Terron, M., Flores, L.J., Koppisepi, S., Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 52 (2007), 11–28.
99. [99] Slominski, R.M., Reiter, R.J., Schlabritz-Loutsevitch, N., Ostrom, R.S., Slominski, A.T., Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol. Cell Endocrinol. 351 (2012), 152–166.
100. [100] Lacoste, B., Angeloni, D., Dominguez-Lopez, S., Calderoni, S., Mauro, A., Fraschini, F., Descarries, L., Gobbi, G., Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J. Pineal Res. 58 (2015), 397–417.
101. [101] Reppert, S.M., Weaver, D.R., Ebisawa, T., Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13 (1994), 1177–1185.
102. [102] Reppert, S.M., Godson, C., Mahle, C.D., Weaver, D.R., Slaugenhaupt, S.A., Gusella, J.F., Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc. Natl. Acad. Sci. USA 92 (1995), 8734–8738.
103. [103] Dubocovich, M.L., Markowska, M., Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27 (2005), 101–110.
104. [104] Tan, D.X., Manchester, L.C., Terron, M.P., Flores, L.J., Tamura, H., Reiter, R.J., Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J. Pineal Res 43 (2007), 317–320.
105. [105] Witt-Enderby, P.A., Bennett, J., Jarzynka, M.J., Firestine, S., Melan, M.A., Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci. 72 (2003), 2183–2198.
106. [106] Brydon, L., Roka, F., Petit, L., de Coppet, P., Tissot, M., Barrett, P., Morgan, P.J., Nanoff, C., Strosberg, A.D., Jockers, R., Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol. Endocrinol. 13 (1999), 2025–2038.
107. [107] Ho, M.K., Yung, L.Y., Chan, J.S., Chan, J.H., Wong, C.S., Wong, Y.H., Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C. Br. J. Pharm. 132 (2001), 1431–1440.
108. [108] Niles, L.P., Hashemi, F., Picomolar-affinity binding and inhibition of adenylate cyclase activity by melatonin in Syrian hamster hypothalamus. Cell Mol. Neurobiol. 10 (1990), 553–558.
109. [109] Morgan, P.J., Barrett, P., Howell, H.E., Helliwell, R., Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24 (1994), 101–146.
110. [110] Chern, C.M., Liao, J.F., Wang, Y.H., Shen, Y.C., Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. Free Radic. Biol. Med. 52 (2012), 1634–1647.
111. [111] Lee, C.H., Yoo, K.Y., Choi, J.H., Park, O.K., Hwang, I.K., Kwon, Y.G., Kim, Y.M., Won, M.H., Melatonin's protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor. J. Neurosci. Res. 88 (2010), 2630–2640.
112. [112] Parada, E., Buendia, I., Leon, R., Negredo, P., Romero, A., Cuadrado, A., Lopez, M.G., Egea, J., Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. J. Pineal Res. 56 (2014), 204–212.
113. [113] Kilic, U., Yilmaz, B., Ugur, M., Yuksel, A., Reiter, R.J., Hermann, D.M., Kilic, E., Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J. Pineal Res. 52 (2012), 228–235.
114. [114] Camello-Almaraz, C., Gomez-Pinilla, P.J., Pozo, M.J., Camello, P.J., Age-related alterations in Ca2+ signals and mitochondrial membrane potential in exocrine cells are prevented by melatonin. J. Pineal Res. 45 (2008), 191–198.
115. [115] Tjong, Y.W., Li, M.F., Hung, M.W., Fung, M.L., Melatonin ameliorates hippocampal nitric oxide production and large conductance calcium-activated potassium channel activity in chronic intermittent hypoxia. J. Pineal Res. 44 (2008), 234–243.
116. [116] Koh, P.O., Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J. Pineal Res. 53 (2012), 358–365.
117. [117] Sun, F.Y., Lin, X., Mao, L.Z., Ge, W.H., Zhang, L.M., Huang, Y.L., Gu, J., Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J. Pineal Res. 33 (2002), 48–56.
118. [118] Hermann, D.M., Kilic, E., Hata, R., Hossmann, K.A., Mies, G., Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice. Neuroscience 104 (2001), 947–955.
119. [119] Kilic, E., Kilic, U., Yulug, B., Hermann, D.M., Reiter, R.J., Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J. Pineal Res. 36 (2004), 171–176.
120. [120] Koh, P.O., Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3. J. Pineal Res. 44 (2008), 101–106.
121. [121] Andrabi, S.A., Sayeed, I., Siemen, D., Wolf, G., Horn, T.F., Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. 18 (2004), 869–871.
122. [122] Datta, S.R., Brunet, A., Greenberg, M.E., Cellular survival: a play in three Akts. Genes Dev. 13 (1999), 2905–2927.
123. [123] Kilic, U., Kilic, E., Reiter, R.J., Bassetti, C.L., Hermann, D.M., Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J. Pineal Res. 38 (2005), 67–71.
124. [124] Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G., Lipton, S.A., Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4 (1998), 228–231.
125. [125] Kilic, E., Bahr, M., Hermann, D.M., Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 32 (2001), 2641–2647.
126. [126] Kilic, E., Kilic, U., Matter, C.M., Luscher, T.F., Bassetti, C.L., Hermann, D.M., Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke 36 (2005), 332–336.
127. [127] Montaner, J., Alvarez-Sabin, J., Molina, C.A., Angles, A., Abilleira, S., Arenillas, J., Monasterio, J., Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32 (2001), 2762–2767.
128. [128] Swarnakar, S., Paul, S., Singh, L.P., Reiter, R.J., Matrix metalloproteinases in health and disease: regulation by melatonin. J. Pineal Res. 50 (2011), 8–20.
129. [129] Gasche, Y., Copin, J.C., Sugawara, T., Fujimura, M., Chan, P.H., Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 21 (2001), 1393–1400.
130. [130] Hung, Y.C., Chen, T.Y., Lee, E.J., Chen, W.L., Huang, S.Y., Lee, W.T., Lee, M.Y., Chen, H.Y., Wu, T.S., Melatonin decreases matrix metalloproteinase-9 activation and expression and attenuates reperfusion-induced hemorrhage following transient focal cerebral ischemia in rats. J. Pineal Res. 45 (2008), 459–467.
131. [131] Jang, J.W., Lee, J.K., Lee, M.C., Piao, M.S., Kim, S.H., Kim, H.S., Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. J. Neurol. Sci. 323 (2012), 221–227.
132. [132] Kim, S.J., Lee, S.R., Protective effect of melatonin against transient global cerebral ischemia-induced neuronal cell damage via inhibition of matrix metalloproteinase-9. Life Sci. 94 (2014), 8–16.
133. [133] Alluri, H., Wilson, R.L., Anasooya Shaji, C., Wiggins-Dohlvik, K., Patel, S., Liu, Y., Peng, X., Beeram, M.R., Davis, M.L., Huang, J.H., Tharakan, B., Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition. PLoS One, 11, 2016, e0154427.
134. [134] Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., Cobb, M.H., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001), 153–183.
135. [135] Bonni, A., Brunet, A., West, A.E., Datta, S.R., Takasu, M.A., Greenberg, M.E., Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 (1999), 1358–1362.
136. [136] Koh, P.O., Melatonin attenuates the cerebral ischemic injury via the MEK/ERK/p90RSK/bad signaling cascade. J. Vet. Med. Sci. 70 (2008), 1219–1223.
137. [137] Abbott, N.J., Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 (2002), 629–638.
138. [138] Lo, A.C., Chen, A.Y., Hung, V.K., Yaw, L.P., Fung, M.K., Ho, M.C., Tsang, M.C., Chung, S.S., Chung, S.K., Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. J. Cereb. Blood Flow. Metab. 25 (2005), 998–1011.
139. [139] Kilic, E., Kilic, U., Reiter, R.J., Bassetti, C.L., Hermann, D.M., Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J. Pineal Res 37 (2004), 247–251.
140. [140] Lajarin-Cuesta, R., Arribas, R.L., De Los Rios, C., Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005–2015). Expert Opin. Ther. Pat. 26 (2016), 389–407.
141. [141] Gong, C.X., Iqbal, K., Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15 (2008), 2321–2328.
142. [142] Sontag, E., Luangpirom, A., Hladik, C., Mudrak, I., Ogris, E., Speciale, S., White, C.L. 3rd, Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol. 63 (2004), 287–301.
143. [143] Ruediger, R., Pham, H.T., Walter, G., Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20 (2001), 10–15.
144. [144] Ling, S., Sun, Q., Li, Y., Zhang, L., Zhang, P., Wang, X., Tian, C., Li, Q., Song, J., Liu, H., Kan, G., Cao, H., Huang, Z., Nie, J., Bai, Y., Chen, S., Li, Y., He, F., Zhang, L., Li, Y., CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A. Circulation 126 (2012), 3028–3040.
145. [145] Mandavia, C., Sowers, J.R., Phosphoprotein phosphatase PP2A regulation of insulin receptor substrate 1 and insulin metabolic signaling. Cardiorenal Med. 2 (2012), 308–313.
146. [146] Liu, F., Grundke-Iqbal, I., Iqbal, K., Gong, C.X., Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22 (2005), 1942–1950.
147. [147] Grallert, A., Boke, E., Hagting, A., Hodgson, B., Connolly, Y., Griffiths, J.R., Smith, D.L., Pines, J., Hagan, I.M., A PP1-PP2A phosphatase relay controls mitotic progression. Nature 517 (2015), 94–98.
148. [148] Luo, D.J., Feng, Q., Wang, Z.H., Sun, D.S., Wang, Q., Wang, J.Z., Liu, G.P., Knockdown of phosphotyrosyl phosphatase activator induces apoptosis via mitochondrial pathway and the attenuation by simultaneous tau hyperphosphorylation. J. Neurochem 130 (2014), 816–825.
149. [149] Shah, F.A., Park, D.J., Gim, S.A., Koh, P.O., Curcumin treatment recovery the decrease of protein phosphatase 2A subunit B induced by focal cerebral ischemia in Sprague-Dawley rats. Lab Anim. Res. 31 (2015), 134–138.
150. [150] Ma, O.K., Sucher, N.J., Molecular interaction of NMDA receptor subunit NR3A with protein phosphatase 2A. Neuroreport 15 (2004), 1447–1450.
151. [151] Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., Janssens, V., Structure, regulation, and pharmacological modulation of PP2A phosphatases. Methods Mol. Biol. 1053 (2013), 283–305.
152. [152] Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., Janssens, V., The Basic Biology of PP2A in Hematologic Cells and Malignancies. Front Oncol., 4, 2014, 347.
153. [153] Lorrio, S., Romero, A., Gonzalez-Lafuente, L., Lajarin-Cuesta, R., Martinez-Sanz, F.J., Estrada, M., Samadi, A., Marco-Contelles, J., Rodriguez-Franco, M.I., Villarroya, M., Lopez, M.G., de los Rios, C., PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice. ACS Chem. Neurosci. 4 (2013), 1267–1277.
154. [154] de Los Rios, C., Egea, J., Marco-Contelles, J., Leon, R., Samadi, A., Iriepa, I., Moraleda, I., Galvez, E., Garcia, A.G., Lopez, M.G., Villarroya, M., Romero, A., Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J. Med. Chem. 53 (2010), 5129–5143.
155. [155] Koh, P.O., Melatonin attenuates decrease of protein phosphatase 2A subunit B in ischemic brain injury. J. Pineal Res. 52 (2012), 57–61.
156. [156] Lajarin-Cuesta, R., Nanclares, C., Arranz-Tagarro, J.A., Gonzalez-Lafuente, L., Arribas, R.L., Araujo de Brito, M., Gandia, L., de Los Rios, C., Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: a New Dual Strategy for the Treatment of Neurodegenerative Diseases. J. Med. Chem. 59 (2016), 6265–6280.
157. [157] Montilla, P., Feijoo, M., Munoz, M.C., Munoz-Castaneda, J.R., Bujalance, I., Tunez, I., Effect of melatonin on the oxidative stress in N1E-115 cells is not mediated by mt1 receptors. J. Physiol. Biochem. 59 (2003), 263–268.
158. [158] Yang, Y., Duan, W., Li, Y., Yan, J., Yi, W., Liang, Z., Wang, N., Yi, D., Jin, Z., New role of silent information regulator 1 in cerebral ischemia. Neurobiol. Aging 34 (2013), 2879–2888.
159. [159] Thompson, J.W., Dave, K.R., Saul, I., Narayanan, S.V., Perez-Pinzon, M.A., Epsilon PKC increases brain mitochondrial SIRT1 protein levels via heat shock protein 90 following ischemic preconditioning in rats. PLoS One, 8, 2013, e75753.
160. [160] Chen, H.Z., Guo, S., Li, Z.Z., Lu, Y., Jiang, D.S., Zhang, R., Lei, H., Gao, L., Zhang, X., Zhang, Y., Wang, L., Zhu, L.H., Xiang, M., Zhou, Y., Wan, Q., Dong, H., Liu, D.P., Li, H., A critical role for interferon regulatory factor 9 in cerebral ischemic stroke. J. Neurosci. 34 (2014), 11897–11912.
161. [161] Carloni, S., Albertini, M.C., Galluzzi, L., Buonocore, G., Proietti, F., Balduini, W., Melatonin reduces endoplasmic reticulum stress and preserves sirtuin 1 expression in neuronal cells of newborn rats after hypoxia-ischemia. J. Pineal Res. 57 (2014), 192–199.
162. [162] Yang, Y., Jiang, S., Dong, Y., Fan, C., Zhao, L., Yang, X., Li, J., Di, S., Yue, L., Liang, G., Reiter, R.J., Qu, Y., Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice. J. Pineal Res. 58 (2015), 61–70.
163. [163] Zhao, L., Liu, H., Yue, L., Zhang, J., Li, X., Wang, B., Lin, Y., Qu, Y., Melatonin Attenuates Early Brain Injury via the Melatonin Receptor/Sirt1/NF-kappaB Signaling Pathway Following Subarachnoid Hemorrhage in Mice. Mol. Neurobiol., 2016.
164. [164] Espinar, A., Garcia-Oliva, A., Isorna, E.M., Quesada, A., Prada, F.A., Guerrero, J.M., Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo. J. Pineal Res. 28 (2000), 81–88.
165. [165] Uz, T., Giusti, P., Franceschini, D., Kharlamov, A., Manev, H., Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience 73 (1996), 631–636.
166. [166] Giusti, P., Lipartiti, M., Franceschini, D., Schiavo, N., Floreani, M., Manev, H., Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J. 10 (1996), 891–896.
167. [167] Giusti, P., Franceschini, D., Petrone, M., Manev, H., Floreani, M., In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin. J. Pineal Res. 20 (1996), 226–231.
168. [168] Floreani, M., Skaper, S.D., Facci, L., Lipartiti, M., Giusti, P., Melatonin maintains glutathione homeostasis in kainic acid-exposed rat brain tissues. FASEB J. 11 (1997), 1309–1315.
169. [169] Lee, Y.K., Lee, S.R., Kim, C.Y., Melatonin attenuates the changes in polyamine levels induced by systemic kainate administration in rat brains. J. Neurol. Sci. 178 (2000), 124–131.
170. [170] Cazevieille, C., Safa, R., Osborne, N.N., Melatonin protects primary cultures of rat cortical neurones from NMDA excitotoxicity and hypoxia/reoxygenation. Brain Res. 768 (1997), 120–124.
171. [171] Das, A., McDowell, M., Pava, M.J., Smith, J.A., Reiter, R.J., Woodward, J.J., Varma, A.K., Ray, S.K., Banik, N.L., The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J. Pineal Res. 48 (2010), 157–169.
172. [172] Kim, H.J., Kwon, J.S., Effects of placing micro-implants of melatonin in striatum on oxidative stress and neuronal damage mediated by N-methyl-D-aspartate (NMDA) and non-NMDA receptors. Arch. Pharm. Res. 22 (1999), 35–43.
173. [173] Chung, S.Y., Han, S.H., Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J. Pineal Res. 34 (2003), 95–102.
174. [174] Lee, S.H., Chun, W., Kong, P.J., Han, J.A., Cho, B.P., Kwon, O.Y., Lee, H.J., Kim, S.S., Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus. J. Pineal Res. 40 (2006), 79–85.
175. [175] Das, A., Belagodu, A., Reiter, R.J., Ray, S.K., Banik, N.L., Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J. Pineal Res. 45 (2008), 117–124.
176. [176] Eng, L.F., Ghirnikar, R.S., Lee, Y.L., Glial fibrillary acidic protein: gfap-thirty-one years (1969–2000). Neurochem Res 25 (2000), 1439–1451.
177. [177] Wilhelmsson, U., Bushong, E.A., Price, D.L., Smarr, B.L., Phung, V., Terada, M., Ellisman, M.H., Pekny, M., Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc. Natl. Acad. Sci. USA 103 (2006), 17513–17518.
178. [178] Liu, Z., Chopp, M., Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog. Neurobiol., 2015.
179. [179] Barreto, G.E., Sun, X., Xu, L., Giffard, R.G., Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. PLoS One, 6, 2011, e27881.
180. [180] Balduini, W., Carloni, S., Perrone, S., Bertrando, S., Tataranno, M.L., Negro, S., Proietti, F., Longini, M., Buonocore, G., The use of melatonin in hypoxic-ischemic brain damage: an experimental study. J. Matern Fetal Neonatal Med. 25:Suppl 1 (2012), 119–124.
181. [181] Alonso-Alconada, D., Alvarez, A., Lacalle, J., Hilario, E., Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol. Histopathol. 27 (2012), 771–783.
182. [182] Pei, Z., Cheung, R.T., Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model. J. Pineal Res. 37 (2004), 85–91.
183. [183] Paredes, S.D., Rancan, L., Kireev, R., Gonzalez, A., Louzao, P., Gonzalez, P., Rodriguez-Bobada, C., Garcia, C., Vara, E., Tresguerres, J.A., Melatonin Counteracts at a Transcriptional Level the Inflammatory and Apoptotic Response Secondary to Ischemic Brain Injury Induced by Middle Cerebral Artery Blockade in Aging Rats. Biores Open Access 4 (2015), 407–416.
184. [184] Berger, H.R., Morken, T.S., Vettukattil, R., Brubakk, A.M., Sonnewald, U., Wideroe, M., No improvement of neuronal metabolism in the reperfusion phase with melatonin treatment after hypoxic-ischemic brain injury in the neonatal rat. J. Neurochem. 136 (2016), 339–350.
185. [185] Ozyener, F., Cetinkaya, M., Alkan, T., Goren, B., Kafa, I.M., Kurt, M.A., Koksal, N., Neuroprotective effects of melatonin administered alone or in combination with topiramate in neonatal hypoxic-ischemic rat model. Restor. Neurol. Neurosci. 30 (2012), 435–444.
186. [186] Pei, Z., Cheung, R.T., Melatonin protects SHSY5Y neuronal cells but not cultured astrocytes from ischemia due to oxygen and glucose deprivation. J. Pineal Res. 34 (2003), 194–201.
187. [187] Jin, R., Yang, G., Li, G., Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87 (2010), 779–789.
188. [188] Emsley, H.C., Hopkins, S.J., Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol. 7 (2008), 341–353.
189. [189] McColl, B.W., Allan, S.M., Rothwell, N.J., Systemic infection, inflammation and acute ischemic stroke. Neuroscience 158 (2009), 1049–1061.
190. [190] Barone, F.C., Feuerstein, G.Z., Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow. Metab. 19 (1999), 819–834.
191. [191] Hanisch, U.K., Kettenmann, H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007), 1387–1394.
192. [192] Morgan, S.C., Taylor, D.L., Pocock, J.M., Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. J. Neurochem. 90 (2004), 89–101.
193. [193] Muller, F.J., Snyder, E.Y., Loring, J.F., Gene therapy: can neural stem cells deliver?. Nat. Rev. Neurosci. 7 (2006), 75–84.
194. [194] Taylor, R.A., Sansing, L.H., Microglial responses after ischemic stroke and intracerebral hemorrhage. Clin. Dev. Immunol., 2013, 2013, 746068.
195. [195] Hu, X., Li, P., Guo, Y., Wang, H., Leak, R.K., Chen, S., Gao, Y., Chen, J., Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43 (2012), 3063–3070.
196. [196] Macleod, M.R., O'Collins, T., Horky, L.L., Howells, D.W., Donnan, G.A., Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J. Pineal Res. 38 (2005), 35–41.
197. [197] Robertson, N.J., Faulkner, S., Fleiss, B., Bainbridge, A., Andorka, C., Price, D., Powell, E., Lecky-Thompson, L., Thei, L., Chandrasekaran, M., Hristova, M., Cady, E.B., Gressens, P., Golay, X., Raivich, G., Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 136 (2013), 90–105.
198. [198] Lee, M.Y., Kuan, Y.H., Chen, H.Y., Chen, T.Y., Chen, S.T., Huang, C.C., Yang, I.P., Hsu, Y.S., Wu, T.S., Lee, E.J., Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J. Pineal Res. 42 (2007), 297–309.
199. [199] Villapol, S., Fau, S., Renolleau, S., Biran, V., Charriaut-Marlangue, C., Baud, O., Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pedia. Res. 69 (2011), 51–55.
200. [200] Welin, A.K., Svedin, P., Lapatto, R., Sultan, B., Hagberg, H., Gressens, P., Kjellmer, I., Mallard, C., Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pedia. Res. 61 (2007), 153–158.
201. [201] Hutton, L.C., Abbass, M., Dickinson, H., Ireland, Z., Walker, D.W., Neuroprotective properties of melatonin in a model of birth asphyxia in the spiny mouse (Acomys cahirinus). Dev. Neurosci. 31 (2009), 437–451.
202. [202] Kahle, K.T., Simard, J.M., Staley, K.J., Nahed, B.V., Jones, P.S., Sun, D., Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport. Physiol. (Bethesda) 24 (2009), 257–265.
203. [203] Kondoh, T., Uneyama, H., Nishino, H., Torii, K., Melatonin reduces cerebral edema formation caused by transient forebrain ischemia in rats. Life Sci. 72 (2002), 583–590.
204. [204] Torii, K., Uneyama, H., Nishino, H., Kondoh, T., Melatonin suppresses cerebral edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by magnetic resonance imaging. J. Pineal Res. 36 (2004), 18–24.
205. [205] Dehghan, F., Khaksari Hadad, M., Asadikram, G., Najafipour, H., Shahrokhi, N., Effect of melatonin on intracranial pressure and brain edema following traumatic brain injury: role of oxidative stresses. Arch. Med. Res. 44 (2013), 251–258.
206. [206] Chen, H.Y., Chen, T.Y., Lee, M.Y., Chen, S.T., Hsu, Y.S., Kuo, Y.L., Chang, G.L., Wu, T.S., Lee, E.J., Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. J. Pineal Res. 41 (2006), 175–182.
207. [207] Kurinczuk, J.J., White-Koning, M., Badawi, N., Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum. Dev. 86 (2010), 329–338.
208. [208] de Haan, M., Wyatt, J.S., Roth, S., Vargha-Khadem, F., Gadian, D., Mishkin, M., Brain and cognitive-behavioural development after asphyxia at term birth. Dev. Sci. 9 (2006), 350–358.
209. [209] Volpe, J.J., Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann. Neurol. 72 (2012), 156–166.
210. [210] Deng, W., Neurobiology of injury to the developing brain. Nat. Rev. Neurol. 6 (2010), 328–336.
211. [211] Volpe, J.J., Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 8 (2009), 110–124.
212. [212] Volpe, J.J., The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Semin Pedia. Neurol. 16 (2009), 167–178.
213. [213] Hossain, M.A., Molecular mediators of hypoxic-ischemic injury and implications for in the developing brain. Epilepsy Behav. 7 (2005), 204–213.
214. [214] Lai, M.C., Yang, S.N., Perinatal hypoxic-ischemic encephalopathy. J. Biomed. Biotechnol., 2011, 2011, 609813.
215. [215] Placha, K., Luptakova, D., Baciak, L., Ujhazy, E., Juranek, I., Neonatal brain injury as a consequence of insufficient cerebral oxygenation. Neuro Endocrinol. Lett. 37 (2016), 79–96.
216. [216] Kartal, O., Aydinoz, S., Kartal, A.T., Kelestemur, T., Caglayan, A.B., Beker, M.C., Karademir, F., Suleymanoglu, S., Kul, M., Yulug, B., Kilic, E., Time dependent impact of perinatal hypoxia on growth hormone, insulin-like growth factor 1 and insulin-like growth factor binding protein-3. Metab. Brain Dis. 31 (2016), 827–835.
217. [217] Leviton, A., Nelson, K.B., Problems with definitions and classifications of newborn encephalopathy. Pedia. Neurol. 8 (1992), 85–90.
218. [218] Levene, M.L., Kornberg, J., Williams, T.H., The incidence and severity of post-asphyxial encephalopathy in full-term infants. Early Hum. Dev. 11 (1985), 21–26.
219. [219] Lee, A.C., Kozuki, N., Blencowe, H., Vos, T., Bahalim, A., Darmstadt, G.L., Niermeyer, S., Ellis, M., Robertson, N.J., Cousens, S., Lawn, J.E., Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pedia. Res 74:Suppl 1 (2013), 50–72.
220. [220] Ahearne, C.E., Boylan, G.B., Murray, D.M., Short and long term prognosis in perinatal asphyxia: an update. World J. Clin. Pedia. 5 (2016), 67–74.
221. [221] Carloni, S., Perrone, S., Buonocore, G., Longini, M., Proietti, F., Balduini, W., Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. J. Pineal Res. 44 (2008), 157–164.
222. [222] Vitte, P.A., Harthe, C., Lestage, P., Claustrat, B., Bobillier, P., Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. J. Pineal Res. 5 (1988), 437–453.
223. [223] Tan, D.X., Manchester, L.C., Reiter, R.J., Qi, W.B., Karbownik, M., Calvo, J.R., Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept 9 (2000), 137–159.
224. [224] Revuelta, M., Arteaga, O., Montalvo, H., Alvarez, A., Hilario, E., Martinez-Ibarguen, A., Antioxidant Treatments Recover the Alteration of Auditory-Evoked Potentials and Reduce Morphological Damage in the Inferior Colliculus after Perinatal Asphyxia in Rat. Brain Pathol. 26 (2016), 186–198.
225. [225] Azzopardi, D.V., Strohm, B., Edwards, A.D., Dyet, L., Halliday, H.L., Juszczak, E., Kapellou, O., Levene, M., Marlow, N., Porter, E., Thoresen, M., Whitelaw, A., Brocklehurst, P., Group, T.S., Moderate hypothermia to treat perinatal asphyxial encephalopathy. N. Engl. J. Med. 361 (2009), 1349–1358.
226. [226] Wood, T., Osredkar, D., Puchades, M., Maes, E., Falck, M., Flatebo, T., Walloe, L., Sabir, H., Thoresen, M., Treatment temperature and insult severity influence the neuroprotective effects of therapeutic hypothermia. Sci. Rep., 6, 2016, 23430.
227. [227] Gancia, P., Pomero, G., Therapeutic hypothermia in the prevention of hypoxic-ischaemic encephalopathy: new categories to be enrolled. J. Matern Fetal Neonatal Med. 25:Suppl 4 (2012), S94–S96.
228. [228] Chen, J., Chen, Y.H., Lv, H.Y., Chen, L.T., Effect of hyperbaric oxygen on lipid peroxidation and visual development in neonatal rats with hypoxia-ischemia brain damage. Biomed. Rep. 5 (2016), 136–140.
229. [229] Liu, X.H., Zhao, Y.L., Ma, Q.M., Zhou, X.H., Wang, Y., [Hyperbaric oxygen improves long-term learning-memory deficits and brain injury in neonatal rat with hypoxia-ischemia brain damage]. Sichuan Da Xue Xue Bao Yi Xue Ban. 38 (2007), 73–77.
230. [230] Yin, X., Meng, F., Wang, Y., Wei, W., Li, A., Chai, Y., Feng, Z., Effect of hyperbaric oxygen on neurological recovery of neonatal rats following hypoxic-ischemic brain damage and its underlying mechanism. Int J. Clin. Exp. Pathol. 6 (2013), 66–75.
231. [231] Li, J., Yawno, T., Sutherland, A., Loose, J., Nitsos, I., Bischof, R., Castillo-Melendez, M., McDonald, C.A., Wong, F.Y., Jenkin, G., Miller, S.L., Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells. Exp. Neurol. 283 (2016), 179–187.
232. [232] Ophelders, D.R., Wolfs, T.G., Jellema, R.K., Zwanenburg, A., Andriessen, P., Delhaas, T., Ludwig, A.K., Radtke, S., Peters, V., Janssen, L., Giebel, B., Kramer, B.W., Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl. Med. 5 (2016), 754–763.
233. [233] Sun, Y., Li, T., Xie, C., Zhang, Y., Zhou, K., Wang, X., Blomgren, K., Zhu, C., Dichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal mice. Oncotarget, 2016.
234. [234] Zhao, H., Mitchell, S., Koumpa, S., Cui, Y.T., Lian, Q., Hagberg, H., Johnson, M.R., Takata, M., Ma, D., Heme Oxygenase-1 Mediates Neuroprotection Conferred by Argon in Combination with Hypothermia in Neonatal Hypoxia-Ischemia Brain Injury. Anesthesiology 125 (2016), 180–192.
235. [235] Fan, X., Kavelaars, A., Heijnen, C.J., Groenendaal, F., van Bel, F., Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury. Curr. Neuropharmacol. 8 (2010), 324–334.
236. [236] Broad, K.D., Fierens, I., Fleiss, B., Rocha-Ferreira, E., Ezzati, M., Hassell, J., Alonso-Alconada, D., Bainbridge, A., Kawano, G., Ma, D., Tachtsidis, I., Gressens, P., Golay, X., Sanders, R.D., Robertson, N.J., Inhaled 45-50% argon augments hypothermic brain protection in a piglet model of perinatal asphyxia. Neurobiol. Dis. 87 (2016), 29–38.
237. [237] Cuzzocrea, S., Reiter, R.J., Pharmacological actions of melatonin in acute and chronic nflammation. Curr. Top. Med. Chem. 2 (2002), 153–165.
238. [238] Esih, K., Goricar, K., Dolzan, V., Rener-Primec, Z., The association between antioxidant enzyme polymorphisms and cerebral palsy after perinatal hypoxic-ischaemic encephalopathy. Eur. J. Paediatr. Neurol., 2016.
239. [239] Tutunculer, F., Eskiocak, S., Basaran, U.N., Ekuklu, G., Ayvaz, S., Vatansever, U., The protective role of melatonin in experimental hypoxic brain damage. Pedia. Int. 47 (2005), 434–439.
240. [240] Romero, A., Ramos, E., de Los Rios, C., Egea, J., Del Pino, J., Reiter, R.J., A review of metal-catalyzed molecular damage: protection by melatonin. J. Pineal Res. 56 (2014), 343–370.
241. [241] Buonocore, G., Perrone, S., Longini, M., Paffetti, P., Vezzosi, P., Gatti, M.G., Bracci, R., Non protein bound iron as early predictive marker of neonatal brain damage. Brain 126 (2003), 1224–1230.
242. [242] Shadid, M., Buonocore, G., Groenendaal, F., Moison, R., Ferrali, M., Berger, H.M., van Bel, F., Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia. Neurosci. Lett. 248 (1998), 5–8.
243. [243] Signorini, C., Ciccoli, L., Leoncini, S., Carloni, S., Perrone, S., Comporti, M., Balduini, W., Buonocore, G., Free iron, total F-isoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. J. Pineal Res. 46 (2009), 148–154.
244. [244] Galano, A., Medina, M.E., Tan, D.X., Reiter, R.J., Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J. Pineal Res. 58 (2015), 107–116.
245. [245] Alonso-Alconada, D., Alvarez, A., Arteaga, O., Martinez-Ibarguen, A., Hilario, E., Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J. Mol. Sci. 14 (2013), 9379–9395.
246. [246] Qiu, T., Xu, M., Neuroprotective and regenerative effects of melatonin on hypoxic-ischemic brain injury in neonatal rats. Int J. Clin. Exp. Med. 9 (2016), 8014–8022.
247. [247] Fulia, F., Gitto, E., Cuzzocrea, S., Reiter, R.J., Dugo, L., Gitto, P., Barberi, S., Cordaro, S., Barberi, I., Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J. Pineal Res. 31 (2001), 343–349.
248. [248] Biran, V., Phan Duy, A., Decobert, F., Bednarek, N., Alberti, C., Baud, O., Is melatonin ready to be used in preterm infants as a neuroprotectant?. Dev. Med. Child Neurol. 56 (2014), 717–723.
249. [249] Garcia-Chavez, D., Gonzalez-Burgos, I., Letechipia-Vallejo, G., Lopez-Loeza, E., Morali, G., Cervantes, M., Long-term evaluation of cytoarchitectonic characteristics of prefrontal cortex pyramidal neurons, following global cerebral ischemia and neuroprotective melatonin treatment, in rats. Neurosci. Lett. 448 (2008), 148–152.
250. [250] Cho, S., Joh, T.H., Baik, H.H., Dibinis, C., Volpe, B.T., Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res. 755 (1997), 335–338.
251. [251] El-Abhar, H.S., Shaalan, M., Barakat, M., El-Denshary, E.S., Effect of melatonin and nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. J. Pineal Res. 33 (2002), 87–94.
252. [252] Kavakli, A., Sahna, E., Parlakpinar, H., Yahsi, S., Ogeturk, M., Acet, A., The effects of melatonin on focal cerebral ischemia-reperfusion model. Saudi Med. J. 25 (2004), 1751–1752.
253. [253] Deykun, K., Pometlova, M., Schutova, B., Mares, J., Modulations of behavioral consequences of minor cortical ischemic lesion by application of free radicals scavengers. Gen. Physiol. Biophys. 30 (2011), 263–270.
254. [254] Reiter, R.J., Melchiorri, D., Sewerynek, E., Poeggeler, B., Barlow-Walden, L., Chuang, J., Ortiz, G.G., Acuna-Castroviejo, D., A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 18 (1995), 1–11.
255. [255] Hardeland, R., Cardinali, D.P., Brown, G.M., Pandi-Perumal, S.R., Melatonin and brain inflammaging. Prog. Neurobiol. 127–128 (2015), 46–63.
256. [256] Reiter, R.J., Tan, D.X., Osuna, C., Gitto, E., Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci. 7 (2000), 444–458.
257. [257] Jou, M.J., Peng, T.I., Reiter, R.J., Jou, S.B., Wu, H.Y., Wen, S.T., Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res. 37 (2004), 55–70.
258. [258] Leon, J., Acuna-Castroviejo, D., Escames, G., Tan, D.X., Reiter, R.J., Melatonin mitigates mitochondrial malfunction. J. Pineal Res. 38 (2005), 1–9.
259. [259] Andrabi, S.S., Parvez, S., Tabassum, H., Melatonin and Ischemic Stroke: mechanistic Roles and Action. Adv. Pharm. Sci., 2015, 2015, 384750.
260. [260] Letechipia-Vallejo, G., Lopez-Loeza, E., Espinoza-Gonzalez, V., Gonzalez-Burgos, I., Olvera-Cortes, M.E., Morali, G., Cervantes, M., Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats. J. Pineal Res. 42 (2007), 138–146.
261. [261] Gonzalez-Burgos, I., Letechipia-Vallejo, G., Lopez-Loeza, E., Morali, G., Cervantes, M., Long-term study of dendritic spines from hippocampal CA1 pyramidal cells, after neuroprotective melatonin treatment following global cerebral ischemia in rats. Neurosci. Lett. 423 (2007), 162–166.
262. [262] Block, F., Global ischemia and behavioural deficits. Prog. Neurobiol. 58 (1999), 279–295.
263. [263] Henrich-Noack, P., Krautwald, K., Reymann, K.G., Wetzel, W., Effects of transient global ischaemia on freezing behaviour and activity in a context-dependent fear conditioning task-implications for memory investigations. Brain Res. Bull. 85 (2011), 346–353.
264. [264] Rennie, K., de Butte, M., Frechette, M., Pappas, B.A., Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome. J. Pineal Res. 44 (2008), 149–156.
265. [265] Juan, W.S., Huang, S.Y., Chang, C.C., Hung, Y.C., Lin, Y.W., Chen, T.Y., Lee, A.H., Lee, A.C., Wu, T.S., Lee, E.J., Melatonin improves neuroplasticity by upregulating the growth-associated protein-43 (GAP-43) and NMDAR postsynaptic density-95 (PSD-95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebral ischemia even during a long-term recovery period. J. Pineal Res. 56 (2014), 213–223.
266. [266] Chi, O.Z., Wei, H.M., Sinha, A.K., Weiss, H.R., Effects of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia. Pharmacology 48 (1994), 367–373.
267. [267] Song, J., Kang, S.M., Lee, W.T., Park, K.A., Lee, K.M., Lee, J.E., The beneficial effect of melatonin in brain endothelial cells against oxygen-glucose deprivation followed by reperfusion-induced injury. Oxid. Med. Cell Longev., 2014, 2014, 639531.
268. [268] Moretti, R., Zanin, A., Pansiot, J., Spiri, D., Manganozzi, L., Kratzer, I., Favero, G., Vasiljevic, A., Rinaldi, V.E., Pic, I., Massano, D., D'Agostino, I., Baburamani, A., La Rocca, M.A., Rodella, L.F., Rezzani, R., Ek, J., Strazielle, N., Ghersi-Egea, J.F., Gressens, P., Titomanlio, L., Melatonin reduces excitotoxic blood-brain barrier breakdown in neonatal rats. Neuroscience 311 (2015), 382–397.
269. [269] Grossetete, M., Phelps, J., Arko, L., Yonas, H., Rosenberg, G.A., Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65 (2009), 702–708.
270. [270] Zhao, C., Deng, W., Gage, F.H., Mechanisms and functional implications of adult neurogenesis. Cell 132 (2008), 645–660.
271. [271] Kim, M.J., Kim, H.K., Kim, B.S., Yim, S.V., Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats. J. Pineal Res. 37 (2004), 193–197.
272. [272] Ayao, M.S., Olaleyer, O., Ihunwo, A.O., Melatonin Potentiates Cells Proliferation in the Dentate Gyrus Following Ischemic Brain Injury in Adult Rats. J. Anim. Vet. Adv. 9 (2010), 1633–1638.
273. [273] Kilic, E., Kilic, U., Bacigaluppi, M., Guo, Z., Abdallah, N.B., Wolfer, D.P., Reiter, R.J., Hermann, D.M., Bassetti, C.L., Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. J. Pineal Res. 45 (2008), 142–148.
274. [274] Roh, J.K., Jung, K.H., Chu, K., Adult stem cell transplantation in stroke: its limitations and prospects. Curr. Stem Cell Res. Ther. 3 (2008), 185–196.
275. [275] Tang, Y., Cai, B., Yuan, F., He, X., Lin, X., Wang, J., Wang, Y., Yang, G.Y., Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia. Cell Transpl. 23 (2014), 1279–1291.
276. [276] Lee, M., Lee, S., Hong, Y., Melatonin plus treadmill exercise synergistically promotes neurogenesis and reduce apoptosis in focal cerebral ischemic rats (877.17). FASEB J., 28, 2014.
277. [277] Hong, Y., Palaksha, K.J., Park, K., Park, S., Kim, H.D., Reiter, R.J., Chang, K.T., Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury. J. Pineal Res. 49 (2010), 201–209.
278. [278] Whishaw, I.Q., O'Connor, W.T., Dunnett, S.B., The contributions of motor cortex, nigrostriatal dopamine and caudate-putamen to skilled forelimb use in the rat. Brain 109:Pt 5 (1986), 805–843.
279. [279] Nagasawa, H., Kogure, K., Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 20 (1989), 1037–1043.
280. [280] Sakatani, K., Iizuka, H., Young, W., Somatosensory evoked potentials in rat cerebral cortex before and after middle cerebral artery occlusion. Stroke 21 (1990), 124–132.
281. [281] Lee, E.J., Lee, M.Y., Chen, H.Y., Hsu, Y.S., Wu, T.S., Chen, S.T., Chang, G.L., Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J. Pineal Res. 38 (2005), 42–52.
282. [282] Lee, E.J., Wu, T.S., Lee, M.Y., Chen, T.Y., Tsai, Y.Y., Chuang, J.I., Chang, G.L., Delayed treatment with melatonin enhances electrophysiological recovery following transient focal cerebral ischemia in rats. J. Pineal Res. 36 (2004), 33–42.
283. [283] Chen, H.Y., Hung, Y.C., Chen, T.Y., Huang, S.Y., Wang, Y.H., Lee, W.T., Wu, T.S., Lee, E.J., Melatonin improves presynaptic protein, SNAP-25, expression and dendritic spine density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats. J. Pineal Res. 47 (2009), 260–270.
284. [284] Vlkolinsky, R., Stolc, S., Effects of stobadine, melatonin, and other antioxidants on hypoxia/reoxygenation-induced synaptic transmission failure in rat hippocampal slices. Brain Res. 850 (1999), 118–126.
285. [285] Pang, S.F., Li, Y., Jiang, D.H., Chang, B., Xie, B.L., Acute cerebral hemorrhage changes the nocturnal surge of plasma melatonin in humans. J. Pineal Res. 9 (1990), 193–208.
286. [286] Chen, J., Wang, L., Wu, C., Hu, Q., Gu, C., Yan, F., Li, J., Yan, W., Chen, G., Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage. J. Pineal Res. 56 (2014), 12–19.
287. [287] Chen, J., Chen, G., Li, J., Qian, C., Mo, H., Gu, C., Yan, F., Yan, W., Wang, L., Melatonin attenuates inflammatory response-induced brain edema in early brain injury following a subarachnoid hemorrhage: a possible role for the regulation of pro-inflammatory cytokines. J. Pineal Res. 57 (2014), 340–347.
288. [288] Wang, Z., Wu, L., You, W., Ji, C., Chen, G., Melatonin alleviates secondary brain damage and neurobehavioral dysfunction after experimental subarachnoid hemorrhage: possible involvement of TLR4-mediated inflammatory pathway. J. Pineal Res. 55 (2013), 399–408.
289. [289] Fang, Q., Chen, G., Zhu, W., Dong, W., Wang, Z., Influence of melatonin on cerebrovascular proinflammatory mediators expression and oxidative stress following subarachnoid hemorrhage in rabbits. Mediat. Inflamm., 2009, 2009, 426346.
290. [290] Wang, Z., Ma, C., Meng, C.J., Zhu, G.Q., Sun, X.B., Huo, L., Zhang, J., Liu, H.X., He, W.C., Shen, X.M., Shu, Z., Chen, G., Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model. J. Pineal Res. 53 (2012), 129–137.
291. [291] Ersahin, M., Toklu, H.Z., Cetinel, S., Yuksel, M., Yegen, B.C., Sener, G., Melatonin reduces experimental subarachnoid hemorrhage-induced oxidative brain damage and neurological symptoms. J. Pineal Res. 46 (2009), 324–332.
292. [292] Aladag, M.A., Turkoz, Y., Parlakpinar, H., Ozen, H., Egri, M., Unal, S.C., Melatonin ameliorates cerebral vasospasm after experimental subarachnoidal haemorrhage correcting imbalance of nitric oxide levels in rats. Neurochem. Res. 34 (2009), 1935–1944.
293. [293] Ueda, Y., Masuda, T., Ishida, A., Misumi, S., Shimizu, Y., Jung, C.G., Hida, H., Enhanced electrical responsiveness in the cerebral cortex with oral melatonin administration after a small hemorrhage near the internal capsule in rats. J. Neurosci. Res. 92 (2014), 1499–1508.
294. [294] Lekic, T., Hartman, R., Rojas, H., Manaenko, A., Chen, W., Ayer, R., Tang, J., Zhang, J.H., Protective effect of melatonin upon neuropathology, striatal function, and memory ability after intracerebral hemorrhage in rats. J. Neurotrauma 27 (2010), 627–637.
295. [295] Li, Z.Q., Liang, G.B., Xue, Y.X., Liu, Y.H., Effects of combination treatment of dexamethasone and melatonin on brain injury in intracerebral hemorrhage model in rats. Brain Res. 1264 (2009), 98–103.
296. [296] Charidimou, A., Nicoll, J.A., McCarron, M.O., Thrombolysis-related intracerebral hemorrhage and cerebral amyloid angiopathy: accumulating evidence. Front Neurol., 6, 2015, 99.
297. [297] Zhang, S., Wang, P., Ren, L., Hu, C., Bi, J., Protective effect of melatonin on soluble Abeta1-42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus. Alzheimers Res. Ther., 8, 2016, 40.
298. [298] Rudnitskaya, E.A., Muraleva, N.A., Maksimova, K.Y., Kiseleva, E., Kolosova, N.G., Stefanova, N.A., Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic alzheimer's disease. J. Alzheimers Dis. 47 (2015), 103–116.
299. [299] O'Neal-Moffitt, G., Delic, V., Bradshaw, P.C., Olcese, J., Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AbetaPP(swe)/PS1 mice. Mol. Neurodegener., 10, 2015, 27.
300. [300] Yang, Y., Li, Q., Shuaib, A., Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 39 (2000), 881–888.
301. [301] Schmid-Elsaesser, R., Hungerhuber, E., Zausinger, S., Baethmann, A., Reulen, H.J., Neuroprotective efficacy of combination therapy with two different antioxidants in rats subjected to transient focal ischemia. Brain Res. 816 (1999), 471–479.
302. [302] Steiner, T., Hacke, W., Combination therapy with neuroprotectants and thrombolytics in acute ischaemic stroke. Eur. Neurol. 40 (1998), 1–8.
303. [303] Chen, T.Y., Lee, M.Y., Chen, H.Y., Kuo, Y.L., Lin, S.C., Wu, T.S., Lee, E.J., Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J. Pineal Res. 40 (2006), 242–250.
304. [304] Gelmers, H.J., Gorter, K., de Weerdt, C.J., Wiezer, H.J., A controlled trial of nimodipine in acute ischemic stroke. N. Engl. J. Med. 318 (1988), 203–207.
305. [305] Toklu, H., Deniz, M., Keyer-Uysal, M., Sener, G., The protective effect of melatonin and amlodipine against cerebral ischemia/reperfusion-induced oxidative brain injury in rats. Marmara Med. J. 22 (2009), 34–44.
306. [306] Gupta, Y.K., Chaudhary, G., Sinha, K., Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat. Can. J. Physiol. Pharm. 80 (2002), 210–217.
307. [307] Campolo, M., Ahmad, A., Crupi, R., Impellizzeri, D., Morabito, R., Esposito, E., Cuzzocrea, S., Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J. Endocrinol. 217 (2013), 291–301.
308. [308] Kelestemur, T., Yulug, B., Caglayan, A.B., Beker, M.C., Kilic, U., Caglayan, B., Yalcin, E., Gundogdu, R.Z., Kilic, E., Targeting different pathophysiological events after traumatic brain injury in mice: role of melatonin and memantine. Neurosci. Lett. 612 (2016), 92–97.
309. [309] Gupta, S., Kaul, C.L., Sharma, S.S., Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats. Neurol. Res. 26 (2004), 103–107.
310. [310] Wang, X., Zhu, S., Pei, Z., Drozda, M., Stavrovskaya, I.G., Del Signore, S.J., Cormier, K., Shimony, E.M., Wang, H., Ferrante, R.J., Kristal, B.S., Friedlander, R.M., Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J. Neurosci. 28 (2008), 9473–9485.
311. [311] Ahmad, A., Khan, M.M., Ishrat, T., Khan, M.B., Khuwaja, G., Raza, S.S., Shrivastava, P., Islam, F., Synergistic effect of selenium and melatonin on neuroprotection in cerebral ischemia in rats. Biol. Trace Elem. Res. 139 (2011), 81–96.
312. [312] Liu, L., Cheung, R.T., Effects of pretreatment with a combination of melatonin and electroacupuncture in a rat model of transient focal cerebral ischemia. Evid. Based Complement. Altern. Med., 2013, 2013, 953162.
313. [313] Bubenik, G.A., Konturek, S.J., Melatonin and aging: prospects for human treatment. J. Physiol. Pharmcol. 62 (2011), 13–19.
314. [314] Radogna, F., Diederich, M., Ghibelli, L., Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmcol. 80 (2010), 1844–1852.
315. [315] de la Fuente Revenga, M., Perez, C., Morales-Garcia, J.A., Alonso-Gil, S., Perez-Castillo, A., Caignard, D.H., Yanez, M., Gamo, A.M., Rodriguez-Franco, M.I., Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-beta-carboline (Pinoline) and Melatonin-Pinoline Hybrids. ACS Chem. Neurosci. 6 (2015), 800–810.
316. [316] Buendia, I., Gomez-Rangel, V., Gonzalez-Lafuente, L., Parada, E., Leon, R., Gameiro, I., Michalska, P., Laudon, M., Egea, J., Lopez, M.G., Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology 99 (2015), 187–195.
317. [317] R. León, J. Egea, I. Buendia, E. Parada, E. Navarro, Uso del 3-(2-isotiocianatoetil)−5-metoxi-1H-indol para el tratamiento de enfermedades neurodegenerativas. ES2526979B1, 2015.
318. [318] Egea, J., Buendia, I., Parada, E., Navarro, E., Rada, P., Cuadrado, A., Lopez, M.G., Garcia, A.G., Leon, R., Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a 'drug-prodrug' mechanism of action. Br. J. Pharm. 172 (2015), 1807–1821.
319. [319] M. Laudon, T. Peleg-Shulman, Novel pyrone-indole derivatives and process for their preparation. PCT International Appl.:WO093880, 2007.
320. [320] Buendia, I., Navarro, E., Michalska, P., Gameiro, I., Egea, J., Abril, S., Lopez, A., Gonzalez-Lafuente, L., Lopez, M.G., Leon, R., New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: nrf2-induction, antioxidant effect and neuroprotection. Future Med. Chem. 7 (2015), 1961–1969.
321. [321] Cuadrado, A., Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/beta-TrCP. Free Radic. Biol. Med. 88 (2015), 147–157.
322. [322] Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T., Jordan-Sciutto, K.L., Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 66 (2007), 75–85.
323. [323] Dinkova-Kostova, A.T., Massiah, M.A., Bozak, R.E., Hicks, R.J., Talalay, P., Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA 98 (2001), 3404–3409.
324. [324] Jahnke, G., Marr, M., Myers, C., Wilson, R., Travlos, G., Price, C., Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol. Sci. 50 (1999), 271–279.
325. [325] Cheung, R.T., The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J. Pineal Res. 34 (2003), 153–160.
326. [326] Andersen, L.P., Gogenur, I., Rosenberg, J., Reiter, R.J., The safety of melatonin in humans. Clin. Drug Investig. 36 (2016), 169–175.
327. [327] Harpsoe, N.G., Andersen, L.P., Gogenur, I., Rosenberg, J., Clinical pharmacokinetics of melatonin: a systematic review. Eur. J. Clin. Pharmcol. 71 (2015), 901–909.
328. [328] Scholtens, R.M., van Munster, B.C., van Kempen, M.F., de Rooij, S.E., Physiological melatonin levels in healthy older people: a systematic review. J. Psychosom. Res. 86 (2016), 20–27.
329. [329] Brzezinski, A., Vangel, M.G., Wurtman, R.J., Norrie, G., Zhdanova, I., Ben-Shushan, A., Ford, I., Effects of exogenous melatonin on sleep: a meta-analysis. Sleep. Med. Rev. 9 (2005), 41–50.
330. [330] Gitto, E., Romeo, C., Reiter, R.J., Impellizzeri, P., Pesce, S., Basile, M., Antonuccio, P., Trimarchi, G., Gentile, C., Barberi, I., Zuccarello, B., Melatonin reduces oxidative stress in surgical neonates. J. Pedia. Surg. 39 (2004), 184–189.
331. [331] Garaulet, M., Gomez-Abellan, P., Rubio-Sastre, P., Madrid, J.A., Saxena, R., Scheer, F.A., Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans. Metabolism 64 (2015), 1650–1657.
332. [332] Lane, E.A., Moss, H.B., Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J. Clin. Endocrinol. Metab. 61 (1985), 1214–1216.
333. [333] Tan, D.X., Manchester, L.C., Terron, M.P., Flores, L.J., Reiter, R.J., One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 42 (2007), 28–42.
334. [334] Fisher, M., Feuerstein, G., Howells, D.W., Hurn, P.D., Kent, T.A., Savitz, S.I., Lo, E.H., Group, S., Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40 (2009), 2244–2250.
335. [335] Lapchak, P.A., Zhang, J.H., Noble-Haeusslein, L.J., RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl. Stroke Res. 4 (2013), 279–285.
336. [336] Koh, P.O., Melatonin prevents the injury-induced decline of Akt/forkhead transcription factors phosphorylation. J. Pineal Res. 45 (2008), 199–203.